X4 reports Phase I data for RCC candidate

X4 Pharmaceuticals Inc. (Cambridge, Mass.) reported data from 14 evaluable patients with advanced clear cell renal cell carcinoma (RCC) in the Phase

Read the full 220 word article

User Sign In